Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1646 1653 1674 3783
This examiner grants 71% of resolved cases
Gyan Chandra is an examiner in Tech Center 3700 and Art Unit 1646. The examiner has 1010 resolved cases. This volume of resolutions provides a basis for analyzing the examiner's prosecution patterns. The data offers a view of how applications are examined within this specific technical unit and the examiner's consistency in decision-making over time.
The allowance rate is 71.3 percent. This percentage shows the frequency of grants for applications that reach a final resolution with this examiner. The median days to allowance is 938. This figure indicates the time from filing to the grant of a patent. Practitioners can use this duration to estimate the timeline for their own applications and manage client expectations regarding the prosecution phase.
The interview lift is 27.5 percent. This metric indicates that an interview is associated with an increase in the probability of an allowance. The positive lift suggests that verbal communication is an effective method for resolving rejections with this examiner. Applicants might prioritize scheduling an interview to address the examiner's concerns and potentially accelerate the path to a patent grant.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18591754 | CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS | Non-Final OA | Novo Nordisk A/S |
| 18426412 | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | Non-Final OA | Novo Nordisk A/S |
| 18409277 | THERAPEUTIC USES OF DULAGLUTIDE | Non-Final OA | Eli Lilly and Company |
| 18430757 | THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18041825 | INSULIN RECEPTOR PARTIAL AGONISTS | Non-Final OA | Merck Sharp & Dohme LLC |
| 18271173 | ENGINEERED STABLE ACE2 PROTEIN VARIANTS AS ANTIVIRAL NEBULIZED THERAPEUTICS | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18360393 | POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR | Non-Final OA | Sanofi |
| 18024819 | PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Final Rejection | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 18247235 | PARTICLE BASED FORMULATION OF SARS-COV-2 RECEPTOR BINDING DOMAIN | Final Rejection | The Research Foundation for The State University of New York |
| 18275855 | NON-TERMINAL ANTIBODY DISCOVERY METHODS AND SINGLE CELL ASSAYS | Non-Final OA | AMGEN INC. |
| 18440382 | USE OF ULTRARAPID ACTING INSULIN | Non-Final OA | MannKind Corporation |
| 17862825 | METHODS AND COMPOSITIONS RELATING TO HOT-START, ONE-STEP, REVERSE TRANSCRIPTION-COUPLED PCR | Final Rejection | Wayne State University |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Non-Final OA | HANMI PHARM. CO., LTD. |
| 18274605 | METHOD AND MEANS FOR MODULATING B-CELL MEDIATED IMMUNE RESPONSES | Non-Final OA | UNIVERSITÄT ULM |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy